Short interest in IceCure Medical Ltd (NASDAQ:ICCM) falls 9.2%

IceCure Medical Ltd (NASDAQ:ICCM – Get Free Report ) saw a large decline in short interest in September. As of September 15th, there was short interest totaling 393,100 shares, a decrease of 9.2% from the August 31st total of 432,900 shares. Based on an average trading volume of 542,000 shares, the days-to-cover ratio is currently 0.7 days. About 1.7% of the company’s shares are short sold.

Changes in Analyst Ratings

Separately, HC Wainwright reiterated a “buy” rating and issued a $2.50 price objective on shares of IceCure Medical in a research report on Thursday, September 12th.

Read the latest stock analysis on ICCM

IceCure Medical stock performance

Shares of ICCM stock traded up $0.01 during mid-day trading on Friday, hitting $0.62. The stock had a trading volume of 414,544 shares, compared to its average volume of 518,096. IceCure Medical has a one year low of $0.54 and a one year high of $1.57. The company has a quick ratio of 2.54, a current ratio of 2.97, and a debt-to-equity ratio of 0.03. The company’s 50-day simple moving average is $0.66 and its 200-day simple moving average is $0.90. The firm has a market cap of $28.51 million, a PE ratio of -1.89 and a beta of 0.56.

IceCure Medical (NASDAQ:ICCM – Get Free Report ) last posted its earnings results on Tuesday, August 20th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. IceCure Medical had a negative return on equity of 111.27% and a negative net margin of 410.22%. The business had revenue of $1.01 million during the quarter, compared to analysts’ expectations of $0.90 million. During the same period in the previous year, the firm posted EPS of ($0.09). On average, analysts expect that IceCure Medical will post -0.27 EPS for the current year.

Hedge funds weigh on IceCure Medical

An institutional investor recently bought a new position in shares of IceCure Medical. Renaissance Technologies LLC bought a new position in IceCure Medical Ltd (NASDAQ:ICCM – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned about 0.15% of IceCure Medical at the end of the most recent quarter. 0.62% of the shares are currently owned by institutional investors and hedge funds.

IceCure Medical Company Profile

(Get a free report)

IceCure Medical Ltd, a commercial medical device company, is engaged in the research, development and commercialization of cryoablation systems, disposable devices and tumor treatment technologies. The company offers the ProSense System, a single-probe system for tumor treatment, as well as associated disposables; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery and proctology.

See Also

Get news and reviews for IceCure Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for IceCure Medical and related companies with MarketBeat.com ‘s FREE daily email newsletter.